Baloxavir marboxil is in clinical development for the treatment of paediatric patients 1 to <12 years of age with influenza. Influenza or ‘flu’ is a common virus infection which causes high temperature, body aches, tiredness, cough, sore throat, headache, diarrhoea and nausea. Flu is usually spread by coughs and sneezes and occurs in annual flu seasons (commonly October to May). Most cases of flu will resolve within three to seven days. However, flu can be more severe in those who are older, in children and in people with long term health conditions, such as heart disease, asthma or diabetes.
Baloxavir marboxil for treating paediatric patients 1 to <12 years of age with influenza
Baloxavir marboxil is in clinical development for the treatment of paediatric patients 1 to <12 years of age with influenza. Influenza or ‘flu’ is a common virus infection which causes high temperature, body aches, tiredness, cough, sore throat, headache, diarrhoea and nausea.
Interventions:
Baloxavir marboxil (Xofluza; S-033188)
Indications:
Influenza
Therapeutic Areas:
Infectious Disease
Year:
2021